Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
China Pharma Holdings, Inc. Reports Second Quarter 2018 Financial Results 2018-08-15 18:22
Mundipharma brings its cancer supportive care expertise to Vietnam after signing agreement with Helsinn Group for ALOXI(R) (palonosetron HCl) 2018-08-15 18:21
Stealth BioTherapeutics Expands Pipeline, Advances New Compound 2018-08-15 00:00
The Buck Institute, Insilico Medicine, and Juvenescence Found Napa Therapeutics to Develop Drugs to Impede Age-Related Disease 2018-08-14 22:00
Kaneka officially starts continuous manufacturing under GMP 2018-08-14 07:48
China Biologic Names Bing Li as New CEO 2018-08-13 20:00
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Trastuzumab Biosimilar to Treat Breast Cancer 2018-08-10 10:05
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer 2018-08-10 09:24
NCCN Publishes First-Ever U.S. Guidelines for Rare Cancers Associated with Pregnancy 2018-08-09 21:15
BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China 2018-08-09 17:05
I-Mab's Announces China Clinical Trial Approval of Long-acting hGLP-1 to Treat Type 2 Diabetes 2018-08-09 16:16
TOT BIOPHARM raises US$102 million in Series B Financing Round 2018-08-08 19:00
VolitionRx Announces $9 Million Private Placement 2018-08-08 18:00
I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202 2018-08-08 09:01
Ward MM and Adapt Analytics announce a partnership to integrate AI and machine learning into Ward MM's clinical decision support engine 2018-08-07 21:00
Frost & Sullivan Publishes Quarterly Update on Oramed Pharmaceuticals Inc. - Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed's clinical progress meets our expectations, stock target price remains at NIS 53.2. 2018-08-07 20:00
Pfizer's Breakthrough Innovative Drug IBRANCE(R) (palbociclib) Receives Approval in China 2018-08-07 17:35
Sotera Health's Nordion completes the sale of its medical isotopes business to BWXT 2018-08-07 04:32
Adlai Nortye Announces Engagement of Lars E. Birgerson, M.D., Ph.D., as CDO and President/CEO of Adlai Nortye USA 2018-08-07 01:15
JNCCN -- Journal of the National Comprehensive Cancer Network Strengthens Editorial Focus on Original, Impactful Research into Cancer Care Delivery 2018-08-06 21:30
1 697 698 699 700 701 970